Skip to main content

Table 3 Risk Factors for development of rifampicin-resistant TB

From: Experience on the first national anti-TB drug resistance survey (DRS) in Timor-Leste

Variable Level Total TB caes RR-TB cases Odds raion (95% CI) p-value
Treatment history New 844 5   0.11
  Previously treated 73 2 4.7 (0.7–22.4)  
Gender Male 524 4   0.96
  Female 393 3 1.0 (0.2–4.8)  
HIV statusa Negative 904 7   NA
  Positive 12 0 NA  
Age 15–24 223 1   0.99
  0–14 19 0 NA  
  25–34 198 2 4.5 (0.2–43.4)  
  35–44 118 1 1.8 (0.1–47.1)  
  45–54 125 1 1.4 (0.1–36.3)  
  55–64 113 1 2.0 (0.1–50.1)  
  65 +  121 1 1.6 (0.1–41.4)  
Municipality Other municipalities 592 2   0.06
  Dili capital 325 5 4.5 (1.0–31.7)  
  1. Univariate logistic regression analyses of key demographic and clinical variables as potential predictors of rifampicin resistance. Analyses were adjusted by treatment history. Variable levels with zero cases were excluded from the analyses; consequently, no analysis was conducted for HIV, but numbers of rifampicin resistant cases disaggregated by HIV status are included in the table for reference
  2. aHIV status was missing for one patient